BioSpace News Archive

Drug Development

Lilly Launches Direct-to-Consumer Website, Services to Support Weight-Loss Drugs

Eli Lilly on Thursday announced the rollout of a new digital healthcare platform to streamline consumer access to its weight-loss drug Zepbound and other medications.

January 5, 2024
·
2 min read
·
Tyler Patchen
Business

The Therapeutic Areas that Stood Out in BioSpace’s NextGen Class of 2024

The therapeutic targets of many of our top startups are also reflected in recent big biopharma acquisitions and partnerships.

January 5, 2024
·
3 min read
·
Heather McKenzie
Bluebird Secures Second Big Outcomes-Based Coverage Contract for Lyfgenia

Under the deal disclosed Thursday in an SEC filing, bluebird bio doubled the number of covered U.S. patients for its sickle cell gene therapy to a cumulative total of around 200 million people.

January 5, 2024
·
2 min read
·
Tristan Manalac
ADC-Focused OnCusp Therapeutics Emerges with $100M Series A Raise

Targeting the red hot antibody-drug conjugate market, OnCusp Therapeutics is coming out of the gate with $100 million from investors such as Novo Holdings and OrbiMed.

January 5, 2024
·
2 min read
·
Tyler Patchen
Policy

FDA Probes GLP-1 Receptor Agonists on Reports of Suicidal Thoughts, Hair Loss

The regulator is launching an investigation of Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound and other GLP-1 receptor agonists following patient reports of suicidal ideation, alopecia and aspiration.

January 5, 2024
·
2 min read
·
Tristan Manalac
Business

AbbVie Inks Two CAR-T Deals Worth Up to $1.4B with Umoja, Targets Multiple Cancers

The two agreements announced Thursday will allow AbbVie to leverage Umoja Biopharma’s VivoVec delivery platform, which enables patients’ cells to produce their own cancer-fighting CAR-T cells.

January 5, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Opinion: Brain Health Matters; We Must Not Lose Momentum

With recent scientific advances, milestone approvals and increased dealmaking, the future of treatment for neurological diseases looks brighter—but continued investment, collaboration and patient-focused efforts are key.

January 5, 2024
·
5 min read
·
Barry Greene
Radiopharmaceuticals Bring in Big Money to Target Irreversible Tumor Damage

Once dormant due to a lack of commercial success and drug side effects, the radiopharmaceutical space is gaining momentum in the form of increased investment and scientific advances.

January 5, 2024
·
5 min read
·
Aayushi Pratap
Deals

CG Oncology Files for IPO, First Such Filing of 2024

While initial public offering activity was light in 2023, the new year has recorded the first IPO plan—from California-based CG Oncology.

January 5, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Allogene Restructures Pipeline Priorities, Cuts 22% of Workforce to Extend Runway

In a major pivot, Allogene Therapeutics will no longer focus on two of its studies testing blood cancer therapy cema-cel in an effort to extend its financial runway into 2026.

January 5, 2024
·
2 min read
·
Tyler Patchen